Table 1 Demographic and clinical features of patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM)

Patients

148

52 (35.1)

96 (64.9)

-

Age, yrs

47.6 ± 10.6

50.2 ± 9.8

46.2 ± 10.9

0.030

Females

117 (79.1)

37 (71.1)

80 (83.3)

0.127

BMI

23.6 ± 3.5

23.4 ± 2.8

23.7 ± 3.9

0.737

Age at CM onset, yrs

16.8 ± 7.0

16.3 ± 7.3

17.0 ± 6.9

0.589

MMDs/MHDs at baseline

18.8 ± 6.8

11.5 ± 1.7

22.7 ± 5.1

< 0.001

NRS score

8.1 ± 1.1

7.9 ± 1.0

8.2 ± 1.1

0.153

Pain quality

 Pulsating

72 (53.0)

23 (46.9)

49 (56.4)

0.559

 Pressing/tightening

38 (27.9)

15 (30.6)

23 (26.4)

 Other

26 (19.1)

11 (22.5)

15 (17.2)

Unilateral pain

86 (58.1)

31 (59.6)

55 (57.3)

0.663

Unilateral cranial autonomic symptoms

61 (44.9)

22 (44.9)

39 (44.8)

0.994

Allodynia

82 (55.4)

31 (59.6)

51 (53.1)

0.558

Dopaminergic symptoms

104 (93.7)

36 (92.3)

68 (94.4)

0.974

Monthly analgesic medications

18.9 ± 12.7

12.0 ± 3.3

22.5 ± 14.3

< 0.001

MO

69 (71.9)

-

69 (71.9)

-

Duration of MO, yrs

7.3 ± 14.8

-

7.3 ± 14.8

Triptan responders

91 (61.5)

37 (71.1)

54 (56.3)

0.109

Pts using concomitant prophylaxis

46 (32.2)

 Tricyclics

19 (41.3)

5 (33.3)

14 (45.2)

0.877

 Anticonvulsants

20 (43.5)

6 (40.0)

14 (45.2)

 Calcium-channels antagonists

1 (2.2)

-

1 (3.2)

 Serotoninergic antagonists

12 (26.1)

6 (40.0)

6 (19.4)

 Onabotulinum toxin A

2 (4.3)

1 (6.7)

1 (3.2)

Prior treatment failures

4.3 ± 1.4

4.0 ± 1.2

4.4 ± 1.5

0.099

 3–4

99 (66.9)

40 (76.9)

59 (61.5)

0.084

 > 4

49 (33.1)

12 (23.1)

37 (38.5)

Onabotulinum toxin A responders^a

9 (34.6)

5 (62.5)

4 (22.2)

0.122

Pts with ≥ 1 comorbidity

94 (63.5)

32 (61.5)

62 (64.6)

0.850

Pts with psychiatric comorbidities

51 (34.4)

17 (32.7)

34 (35.4)

0.879

HIT-6 score

67.3 ± 5.8

65.6 ± 6.8

68.3 ± 5.0

0.008

MIDAS score

80.3 ± 59.9

62.4 ± 42.0

90.0 ± 65.8

0.023

Fremanezumab dosing regimen

 Monthly

98 (66.2)

38 (73.1)

60 (62.5)

-

 Quarterly

50 (33.8)

14 (26.9)

36 (37.5)